<DOC>
	<DOCNO>NCT01876550</DOCNO>
	<brief_summary>The primary objective study determine comparability safety efficacy Mupirocin Calcium Cream , 2 % Bactroban® Cream subject secondarily infect traumatic skin lesion . It also determine whether efficacy active treatment superior vehicle cream ( placebo ) .</brief_summary>
	<brief_title>A Study Evaluate Safety Bioequivalence Mupirocin Calcium Cream , 2 % Bactroban® Cream Compare Both Vehicle Treatment Secondarily Infected Traumatic Skin Lesions .</brief_title>
	<detailed_description />
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Mupirocin</mesh_term>
	<criteria>Healthy male nonpregnant female age 18 month old secondarily infect traumatic skin lesion laceration , suture wound , abrasion . The laceration suture wound exceed 10 cm length surround erythema 2 cm edge lesion . An abrasion exceed 100 cm2 total area surround erythema 2 cm edge abrasion . Positive baseline culture S. aureus and/or S. pyogenes sample take secondarily infect traumatic skin lesion . Positive Gram stain Wright stain confirmation white blood cell pus/exudate secondarily infect traumatic skin lesion . Skin Infection Rating Scale total score secondarily infect traumatic skin lesion least 8 baseline . Women childbearing potential , addition negative urine pregnancy test , must willing use acceptable form birth control study . Subjects enter study hormonal contraceptive must method least 90 day prior study continue method duration study . Subjects use hormonal contraception stop must stop less 90 day prior study . Subjects 18 year age old must provide Institutional Review Board approve write informed consent . Subjects age 18 year must parent legal guardian provide Institutional Review Board approve write consent . An assent form minor must complete subject legal age consent , depend age range require state law . Subjects must willing able understand comply requirement study , apply medication instruct , return require study visit , comply therapy prohibition , able complete study . Subjects must good health free clinically significant disease , secondarily infect traumatic skin lesion , might interfere study evaluation . Subjects pregnant , nursing , plan pregnancy within study participation period . Any dermatological disorder may interfere evaluation subject 's secondarily infect traumatic skin lesion ( ) . Bacterial skin infection , depth severity , could appropriately treated topical antibiotic . Secondarily infect bite puncture wound . Systemic sign symptoms infection . Requirement surgical intervention treatment infection prior study entry . A subject must receive topical corticosteroid , topical antibiotic , antifungal agent least 48 hour ( 2 day ) prior baseline . A subject must receive systemic antibiotic systemic corticosteroid least 7 day prior baseline . Primary secondary immunodeficiency . Diabetes . Presence medical condition might adversely affect safety study participant confound study result . History hypersensitivity allergy mupirocin and/or study medication ingredient . Subjects consume excessive amount alcohol , abuse drug , condition would compromise compliance protocol . Treatment investigational drug device within 30 day prior study entry . Previously enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Mupirocin Calcium Cream 2 %</keyword>
	<keyword>Bactroban® Cream</keyword>
	<keyword>Secondarily infect traumatic skin lesion</keyword>
</DOC>